Prognostic variables in male breast cancer

John L. Clark, Phuong L. Nguyen, Waclaw B. Jaszcz, Aminah Jatoi, Gloria A. Niehans

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The prognostic role of ploidy status, S phase fraction, estrogen and progesterone receptor status, and the expression of p53 and erbB-2 protein in male breast carcinoma (MBC) remains controversial. The primary objective of this study was to determine which of the common prognostic factors for female breast cancer predict prognosis in MBC. A secondary objective was to assess the impact of comorbid illnesses on survival. A retrospective review of demographic data, surgical treatment, pathological staging, adjuvant treatment and follow-up was completed for 16 patients with MBC (1 intraductal and 15 invasive). Formalin-fixed, paraffin-embedded tissue was processed for ploidy, S phase fraction, and immunohistochemical detection of estrogen and progesterone receptors plus expression of p53 and erbB-2 protein. Six of 15 patients with infiltrating ductal carcinoma are currently alive without evidence of disease and a median survival of 61 months. Nine patients died after a median survival of 52 months, with 6 patients having no evidence of recurrent breast cancer. Two of 3 deaths secondary to advanced breast cancer occurred in patients who initially presented with T 4 lesions and were staged IIIB. Two of 15 tumors were erbB-2 positive, whereas only 1 tested weakly positive for p53 protein. We observed that MBCs express erbB-2 and p53 proteins infrequently. Neither ploidy status, S phase fraction, nor erbB2/p53 status provided any apparent improvement in establishing prognosis beyond routine pathological staging. Advanced TNM stage was associated with diminished survival. The majority of MBCs express estrogen and progesterone receptors. Survivals in MBC were reduced in association with comorbid medical conditions.

Original languageEnglish (US)
Pages (from-to)502-511
Number of pages10
JournalAmerican Surgeon
Volume66
Issue number5
StatePublished - May 2000

Fingerprint

Male Breast Neoplasms
Ploidies
Progesterone Receptors
S Phase
Survival
Estrogen Receptors
Breast Neoplasms
Proteins
Ductal Carcinoma
Paraffin
Formaldehyde
Demography
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Clark, J. L., Nguyen, P. L., Jaszcz, W. B., Jatoi, A., & Niehans, G. A. (2000). Prognostic variables in male breast cancer. American Surgeon, 66(5), 502-511.

Prognostic variables in male breast cancer. / Clark, John L.; Nguyen, Phuong L.; Jaszcz, Waclaw B.; Jatoi, Aminah; Niehans, Gloria A.

In: American Surgeon, Vol. 66, No. 5, 05.2000, p. 502-511.

Research output: Contribution to journalArticle

Clark, JL, Nguyen, PL, Jaszcz, WB, Jatoi, A & Niehans, GA 2000, 'Prognostic variables in male breast cancer', American Surgeon, vol. 66, no. 5, pp. 502-511.
Clark JL, Nguyen PL, Jaszcz WB, Jatoi A, Niehans GA. Prognostic variables in male breast cancer. American Surgeon. 2000 May;66(5):502-511.
Clark, John L. ; Nguyen, Phuong L. ; Jaszcz, Waclaw B. ; Jatoi, Aminah ; Niehans, Gloria A. / Prognostic variables in male breast cancer. In: American Surgeon. 2000 ; Vol. 66, No. 5. pp. 502-511.
@article{cae303693cb2461d9b1885561d572a6a,
title = "Prognostic variables in male breast cancer",
abstract = "The prognostic role of ploidy status, S phase fraction, estrogen and progesterone receptor status, and the expression of p53 and erbB-2 protein in male breast carcinoma (MBC) remains controversial. The primary objective of this study was to determine which of the common prognostic factors for female breast cancer predict prognosis in MBC. A secondary objective was to assess the impact of comorbid illnesses on survival. A retrospective review of demographic data, surgical treatment, pathological staging, adjuvant treatment and follow-up was completed for 16 patients with MBC (1 intraductal and 15 invasive). Formalin-fixed, paraffin-embedded tissue was processed for ploidy, S phase fraction, and immunohistochemical detection of estrogen and progesterone receptors plus expression of p53 and erbB-2 protein. Six of 15 patients with infiltrating ductal carcinoma are currently alive without evidence of disease and a median survival of 61 months. Nine patients died after a median survival of 52 months, with 6 patients having no evidence of recurrent breast cancer. Two of 3 deaths secondary to advanced breast cancer occurred in patients who initially presented with T 4 lesions and were staged IIIB. Two of 15 tumors were erbB-2 positive, whereas only 1 tested weakly positive for p53 protein. We observed that MBCs express erbB-2 and p53 proteins infrequently. Neither ploidy status, S phase fraction, nor erbB2/p53 status provided any apparent improvement in establishing prognosis beyond routine pathological staging. Advanced TNM stage was associated with diminished survival. The majority of MBCs express estrogen and progesterone receptors. Survivals in MBC were reduced in association with comorbid medical conditions.",
author = "Clark, {John L.} and Nguyen, {Phuong L.} and Jaszcz, {Waclaw B.} and Aminah Jatoi and Niehans, {Gloria A.}",
year = "2000",
month = "5",
language = "English (US)",
volume = "66",
pages = "502--511",
journal = "The American surgeon",
issn = "0003-1348",
publisher = "Southeastern Surgical Congress",
number = "5",

}

TY - JOUR

T1 - Prognostic variables in male breast cancer

AU - Clark, John L.

AU - Nguyen, Phuong L.

AU - Jaszcz, Waclaw B.

AU - Jatoi, Aminah

AU - Niehans, Gloria A.

PY - 2000/5

Y1 - 2000/5

N2 - The prognostic role of ploidy status, S phase fraction, estrogen and progesterone receptor status, and the expression of p53 and erbB-2 protein in male breast carcinoma (MBC) remains controversial. The primary objective of this study was to determine which of the common prognostic factors for female breast cancer predict prognosis in MBC. A secondary objective was to assess the impact of comorbid illnesses on survival. A retrospective review of demographic data, surgical treatment, pathological staging, adjuvant treatment and follow-up was completed for 16 patients with MBC (1 intraductal and 15 invasive). Formalin-fixed, paraffin-embedded tissue was processed for ploidy, S phase fraction, and immunohistochemical detection of estrogen and progesterone receptors plus expression of p53 and erbB-2 protein. Six of 15 patients with infiltrating ductal carcinoma are currently alive without evidence of disease and a median survival of 61 months. Nine patients died after a median survival of 52 months, with 6 patients having no evidence of recurrent breast cancer. Two of 3 deaths secondary to advanced breast cancer occurred in patients who initially presented with T 4 lesions and were staged IIIB. Two of 15 tumors were erbB-2 positive, whereas only 1 tested weakly positive for p53 protein. We observed that MBCs express erbB-2 and p53 proteins infrequently. Neither ploidy status, S phase fraction, nor erbB2/p53 status provided any apparent improvement in establishing prognosis beyond routine pathological staging. Advanced TNM stage was associated with diminished survival. The majority of MBCs express estrogen and progesterone receptors. Survivals in MBC were reduced in association with comorbid medical conditions.

AB - The prognostic role of ploidy status, S phase fraction, estrogen and progesterone receptor status, and the expression of p53 and erbB-2 protein in male breast carcinoma (MBC) remains controversial. The primary objective of this study was to determine which of the common prognostic factors for female breast cancer predict prognosis in MBC. A secondary objective was to assess the impact of comorbid illnesses on survival. A retrospective review of demographic data, surgical treatment, pathological staging, adjuvant treatment and follow-up was completed for 16 patients with MBC (1 intraductal and 15 invasive). Formalin-fixed, paraffin-embedded tissue was processed for ploidy, S phase fraction, and immunohistochemical detection of estrogen and progesterone receptors plus expression of p53 and erbB-2 protein. Six of 15 patients with infiltrating ductal carcinoma are currently alive without evidence of disease and a median survival of 61 months. Nine patients died after a median survival of 52 months, with 6 patients having no evidence of recurrent breast cancer. Two of 3 deaths secondary to advanced breast cancer occurred in patients who initially presented with T 4 lesions and were staged IIIB. Two of 15 tumors were erbB-2 positive, whereas only 1 tested weakly positive for p53 protein. We observed that MBCs express erbB-2 and p53 proteins infrequently. Neither ploidy status, S phase fraction, nor erbB2/p53 status provided any apparent improvement in establishing prognosis beyond routine pathological staging. Advanced TNM stage was associated with diminished survival. The majority of MBCs express estrogen and progesterone receptors. Survivals in MBC were reduced in association with comorbid medical conditions.

UR - http://www.scopus.com/inward/record.url?scp=0034024111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034024111&partnerID=8YFLogxK

M3 - Article

C2 - 10824754

AN - SCOPUS:0034024111

VL - 66

SP - 502

EP - 511

JO - The American surgeon

JF - The American surgeon

SN - 0003-1348

IS - 5

ER -